Management of pancreatic adenocarcinoma in Ontario, Canada: a population-based study using novel case ascertainment.
BACKGROUND
Pancreatic adenocarcinoma (PA) is largely incurable, although recent progress has been made in the safety of surgery for PA and in adjuvant and palliative chemotherapy. The purpose of this study was to describe the management of PA in Ontario, Canada.


METHODS
The Pathology Information Management System (PIMS), which uses electronic pathology reporting (E-path), was used to rapidly identify and recruit patients based on a pathologic diagnosis of PA between 2003 and 2006. Patients were mailed questionnaires for additional data.


RESULTS
The patient participation rate was 26% (351 of 1325). Nonresponders were more likely to be older than 70 years (43% v. 28%, p < 0.001) and to have received treatment in nonacademic centres (53% v. 34%, p < 0.001). Fifty-four percent of responders underwent a potentially curative operation, and most (77%) were 70 years or younger (p = 0.03). Completed resections were documented in 83% of patients who underwent exploratory surgery with curative intent; 17% of patients had unresectable and/or metastatic disease at laparotomy. Of the completed resections, 24% were performed in nonacademic centres with a 32% positive margin rate; 76% were performed in academic centres with a 29% positive margin rate (p = 0.84). Resections with curative intent were less frequently aborted in academic centres (10% v. 33%, p < 0.001). Of the patients who responded to our questionnaire, 43% received chemotherapy and 7% participated in clinical trials.


CONCLUSIONS
Despite using PIMS and E-path, the response rate for this study was low (< 30%). Nonresponders were older and more commonly treated in nonacademic centres. Patients undergoing surgery in academic centres had higher resection rates. The rate of adjuvant and palliative chemotherapy was stage-dependent and low.
Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex, 69 Murray Street, Toronto, Ontario. aborgida@mtsinai.on.ca
Ayelet Eppel
AE
Borgida
Shady
S
Ashamalla
Wigdan
W
Al-Sukhni
Heidi
H
Rothenmund
David
D
Urbach
Malcolm
M
Moore
Michelle
M
Cotterchio
Steven
S
Gallinger
D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D016001:Confidence Intervals; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology; D009367:Neoplasm Staging; D016017:Odds Ratio; D009864:Ontario; D010180:Pancreatectomy / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D011159:Population Surveillance; D011379:Prognosis; D018570:Risk Assessment; D011795:Surveys and Questionnaires; D016019:Survival Analysis
Ann Surg. 2007 Aug;246(2):173-80
17667493
J Surg Oncol. 2004 Dec 15;88(4):206-9
15565629
Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):704-10
16614112
Br J Surg. 2004 Nov;91(11):1410-27
15499648
N Engl J Med. 2004 Mar 18;350(12):1200-10
15028824
Ann Surg. 1995 Jan;221(1):59-66
7826162
Arch Surg. 2005 Jun;140(6):584-9; discussion 589-91
15967906
N Engl J Med. 2003 Nov 27;349(22):2117-27
14645640
J Am Coll Surg. 1999 Jul;189(1):1-7
10401733
N Engl J Med. 2002 Apr 11;346(15):1128-37
11948273
N Engl J Med. 1992 Feb 13;326(7):455-65
1732772
J Gastrointest Surg. 2006 Jun;10(6):916-26
16769552
Clin Trials. 2006;3(2):133-41
16773955
J Clin Oncol. 2005 Jun 1;23(16):3802-10
15923574
Br J Cancer. 2005 Mar 14;92(5):971-7
15685231
JAMA. 2004 Jun 9;291(22):2720-6
15187053
CMAJ. 1999 Mar 9;160(5):643-8
10101998